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Calcium and salinity sensing by the thick ascending limb: A
journey from mammals to fish and back again. The roles of the
CaSR in endocrine, epithelial, CNS, and other cells have been
reviewed previously [17–19, 20, 27–30, 31–33]. This brief review
focuses on the roles of the CaSR in the thick ascending limb of
Henle (TAL), and is written in honor of my mentor and long-
term friend and colleague, Thomas E. Andreoli, on the occasion
of his retirement. My early studies of TAL function with Tom
Andreoli were the inspiration for this work.
The maintenance of the ionic composition of body flu-
ids (internal ocean; [1, 2]) is central to health, and dis-
turbances in the body contents and/or concentrations of
ions are common in disease states. The emerging concept
of ion sensors as detectors or “thermostats” in regulating
the internal ocean of organisms has begun to revolution-
ize our understanding of homeostasis. The idea that or-
ganisms had evolved sensors for ions was not new (e.g.,
sodium sensors in the central nervous system for regula-
tion of blood pressure and salt excretion by the kidney),
but was largely abandoned in the late 1980s since no one
had identified a protein or gene for such an inorganic
sensor, and many believed it unlikely that biologic sys-
tems could fashion detectors capable of responding to
small deviations from steady-state ion concentrations in
the millimolar range. In the early 1990s while at Harvard,
my colleague, Dr. Edward M. Brown and I cloned a novel
G protein–coupled receptor, the CaSR, expressed on the
surface of parathyroid chief cells that senses extracellu-
lar calcium and transmits this information via traditional
intracellular second messengers to regulate the release
of parathyroid hormone (PTH) [3, 4]. We subsequently
cloned the same gene from rat kidney [5] and localized
its expression along the nephron [6].
The CaSR is a large glycoprotein that belongs to Fam-
ily C of the superfamily of G protein–coupled receptors
(GPR). The CaSR generates an array of second mes-
sengers in bovine parathyroid cells and human embry-
onic kidney (HEK)293 cells transfected with the human
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CaSR [7]. Although agonist binding is thought to involve
the large extracellular domain [8], parts of the receptor
imbedded in the membrane also appear to be involved in
interacting with allosteric agonists like calcimimetics [9].
The C-terminus is important for cell surface expression
and signal transduction [10–12]. Dimerization (and pos-
sibly higher order multimerization) of the CaSR occurs
with agonist binding [13, 14], involves cysteine residues in
the agonist-binding extracellular domain [15], and is nec-
essary for normal function [14, 16]. The CaSR is unique
in the GPR superfamily for several reasons: (1) calcium
was the primary physiologic ligand establishing an inor-
ganic ion as a first messenger; (2) the EC50 for ionized
calcium was 1.2 millimolar, which is the normal extracel-
lular free calcium concentration in mammals but is orders
of magnitude higher than for ligands to other GPRs; and
(3) despite the millimolar EC50, the receptor activation
curve was steep, establishing that this receptor could de-
tect small changes in calcium concentration in a “sea of
calcium.” This work set off a flurry of research establish-
ing the biologic role of this CaSR in calcium homeostasis
[17–19]. It was unanticipated that this receptor would also
play important roles in regulating salt and water transport
by the kidney [20] and colon [21–24], and in modulating
acid secretion by the stomach [24, 25], as well as in provid-
ing differentiation signals in a variety of epithelial cells
(e.g., skin keratinocytes, mammary gland cells, colono-
cytes). The latter provides a link to the widely accepted
effect of increased dietary calcium intake in reducing the
risk of colon cancer [24, 26]. This basic research has led
to the development of receptor agonists, Cincalcet-HCl
(SensiparTM; Amgen, Thousand Oaks, CA, USA), for use
in treating secondary hyperparathyroidism in renal fail-
ure patients.
CaSR activity sets the plasma calcium concentration and
is crucial for divalent mineral handling by the kidney
Studies of inherited disorders caused by mutations
in the CaSR gene resulting in less than normally ac-
tive (familial hypercalcemic hypocalciuria, or FHH [34])
or overactive (autosomal-dominant hypocalcemia [35])
S-28
Hebert: Calcium and salinity sensing by the TAL S-29
PT
60-70%
DCT/CT
10%
TAL
20%
CD
3-7%
A
R
en
al
 C
a2
+  
e
xc
re
tio
n
4 6 8 10
Serum Ca2+, mg/dL
No
 P
TH
 a
nd
 vi
ta
m
in 
D
Steep slope
No
rm
al
FHH
Loop
diuretic
B
Threshold
Fig. 1. Inter-relationship between plasma Ca2+ and renal Ca2+ excre-
tion. (A) Fractional reabsorption of Ca2+ along the nephron. Ca2+ re-
absorption is regulated by calciotropic hormones and the CaSR in TAL
and DCT/CNT. (B) Relationship between serum calcium and renal cal-
cium excretion. Following a threshold point, renal Ca2+ excretion rises
rapidly with increases in serum Ca2+. In the absence of PTH and vita-
min D, the threshold is left-shifted by the steep relationship between
serum, and urine Ca2+ remains. This steep relationship is absent with
loss-of-function mutations in the CaSR. See text for abbreviations.
receptors have clearly shown that CaSR is the nor-
mal “thermostat” for setting the extracellular Ca2+
concentration. A similar hypercalcemic phenotype is ob-
served when the CasR gene is deleted in the mouse [36].
Regulated excretion of Ca2+ by the kidney is a ma-
jor component of the extracellular homeostatic system
that sets the plasma calcium concentration. Thus, it is not
surprising that the CaSR also provides the crucial “sens-
ing” mechanism for extracellular calcium–mediated reg-
ulation of Ca2+ excretion by the kidney [17, 18, 30, 32, 33,
37]. The relationship between serum ionized Ca2+ and
the magnitude of urinary Ca2+ excretion is quite steep
following a specific threshold point ([38, 39]; Fig. 1B).
While the calciotropic hormones, vitamin D and PTH,
set the threshold point, neither changes the steep serum
Ca2+-urine Ca2+ excretion curve ([38, 39]; Fig. 1B). The
latter suggests that there is an additional regulator of re-
nal Ca2+ excretion, the CaSR.
Expression of the CaSR in the mammalian kidney is
greatest in the thick ascending limb of Henle (TAL),
where regulated reabsorption plays a major role in de-
termining Ca2+ excretion (Fig. 1A). An “experiment of
nature” illustrates the importance of calcium sensing by
the TAL. Individuals with inactivating mutations (FHH)
of the CaSR lose the steep relationship between serum
and urine Ca2+, yet a loop diuretic like furosemide can
still increase Ca2+ excretion ([40]; Fig. 1B). This diuretic
response indicates that the TAL is actively reabsorbing
Ca2+, but is not capable of normally responding to a rise
in extracellular Ca2+ (i.e., has lost its ability to “sense” ex-
tracellular Ca2+). Moreover, CasR- and Gcm2–deficient
mice, lacking parathyroid glands, exhibit hypocalciuria
[41], consistent with the absence of renal Ca2+ sensing
when the CaSR is missing. In addition, CasR gene poly-
morphisms have been suggested to alter susceptibility to
idiopathic hypercalcemia [42].
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Fig. 2. Model of salt transport by the TAL. See text for discussion.
The mechanisms of CaSR action in the TAL
CaSR protein is highly expressed on basolateral mem-
branes in the TAL, where it senses the plasma/interstitial
calcium concentration [6, 43]. Consistent with the baso-
lateral localization, increases in plasma, but not urinary,
Ca2+ (or Mg2+) concentrations modulate NaCl and min-
eral ion transport in the rat loop of Henle [44, 45]. Since
the bulk of regulated divalent mineral reabsorption medi-
ated by the TAL occurs in the CTAL ([44, 46, 47]; Fig. 1B),
the effect of plasma Ca2+ on renal Ca2+(Mg2+) handling
relates to CaSR-dependent regulation in this segment. In
fact, the most intense staining of the CaSR in kidney is in
the cortical TAL [6].
The lumen-positive transepithelial voltage generated
by NaCl reabsorption in the TAL drives divalent mineral
reabsorption primarily via the paracellular route (Fig. 2;
mouse [48, 49]; rat [47]; rabbit [48]). Thus, modulations in
the rate of NaCl reabsorption by the TAL will have a di-
rect effect on divalent mineral reabsorption. Due to this
codependence of sodium and divalent mineral transport
in the TAL, loop diuretics like furosemide increase re-
nal Ca2+ excretion [46]. Similarly, activation of the CaSR
in experimental animals [20, 27] and healthy men [50]
enhances both NaCl and Ca2+ excretion. Furosemide-
induced nephrocalcinosis is reduced by parathyroidec-
tomy or by calcimimetic effects on parathyroid glands
[51], indicating an important role for PTH in addition to
the diuretic effect on the TAL.
Increases in extracellular Ca2+ reduce Cl− transport
in CTAL by 25% to 30% [52, 53]. At least two second
messenger systems that are involved in regulation of salt
transport by the TAL are modulated by activation of
the CaSR. In CTAL, a number of hormones, coupled
to Gs-linked receptors, generate cyclic AMP and stim-
ulate NaCl and divalent mineral reabsorption (e.g., AVP,
PTH, glucagon, calcitonin [44, 54]). Increases in extra-
cellular Ca2+ reduce AVP-stimulated cyclic AMP pro-
duction, and enhance cyclic AMP destruction in isolated
mouse [55, 56] and rat [52, 57] TAL segments (Fig. 3A).
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Fig. 3. Mechanisms for CaSR modulation of salt transport in the TAL. (A) Modulation of Ca2+/Mg2+ transport by CaSR-mediated reduction in
cellular cyclic AMP. (B) Modulation of Ca2+/Mg2+ transport by CaSR-mediated activation of P450 and generation of 20-HETE. CaSR activation
also increases cyclooxygenase-2 (COX-2), resulting in increased PGE2 production. See text for discussion.
The CaSR agonist-dependent rise in Ca2+ i is mainly thap-
sigargin insensitive, depends on Ca2+ uptake from extra-
cellular fluid [53, 57], and is independent of phospholipase
A2 (PLA2) and PLC activation L [52]. Increases in in-
tracellular Ca2+ inhibit cyclic AMP generation via a
Ca2+-inhibitable adenylate cyclase isoform, and increase
destruction by activation of Ca2+-dependent phosphodi-
esterases [57].
Other studies in rat TAL have suggested an addi-
tional mechanism for modulation of salt transport by
CaSR activation ([58]; Fig. 3B). While PLA2 may play
no role in the modulation of cyclic AMP, Ca2+ can acti-
vate this lipase in TAL [58], resulting in increased cy-
tosolic arachidonic acid (AA). The AA can then be
metabolized by a P450 x-hydroxylase to 20-HETE or
by cyclooxygenbase-2 (COX-2) to prostaglandins. Nor-
mally, the balance favors 20-HETE as the P450 is more
highly expressed. Consistent with this hypothesis, CaSR
agonists increase 20-HETE production in the CTAL [58].
20-HETE reduces renal salt transport in the TAL [58–61]
by inhibiting Na-K-2Cl cotransport [62], apical K+ recy-
cling channels [63, 64], and Na-K-ATPase [59] activities.
The PLA2→AA→P450→20-HETE pathway is also in-
volved in the inhibition of salt transport in the TAL by
angiotensin II [65, 66] and bradykinin [67]. Moreover,
exogenous AA can inhibit adenylate cyclase activity in
CTAL, which would further inhibit NaCl and divalent
mineral transport [68]. Finally, CaSR agonists increase
TNFa, which in turn stimulates the production of COX-2
[69–71], diverting AA metabolism toward prostaglandins
(Fig. 3B). The subsequent production of PGE2 may also
contribute to modulation of salt transport in the TAL
[72].
The CaSR is also expressed at basolateral membranes
of the MTAL, where similar mechanisms regulate NaCl
reabsorption, and thereby modulate the countercurrent
mechanism. We have suggested that the CaSR effect in
this nephron segment is important to ensure that divalent
minerals are excreted in a more dilute urine, which would
reduce the risk of stone formation or nephrocalcinosis
[33]. With pathologic increases in extracellular Ca2+, the
overactivation of the CaSR would contribute to genera-
tion of the associated nephrogenic diabetes insipidus.
Lessons from fish—A role for salinity sensing by the
CaSR in the mTAL
The CaSR is activated by increases in extracellular
Ca2+ concentrations, but the EC50 for Ca2+ activation
can be shifted by extracellular polyamines and amino
acids or amino acids—increases in the concentrations of
these nutrients lower the EC50 for Ca2+ [27]. The phys-
iologic relevance for the allosteric modifying effects of
these nutrients is just beginning to be understood for the
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Fig. 4. The CaSR as a salinity sensor in the thick ascending limb of
Henle. Increases in basolateral salinity reduce the affinity of the recep-
tor for Ca2+. This effect helps to maintain continued Ca2+ reabsorption
even when Ca2+ accumulates at the basolateral side of the TAL cell.
See text for discussion.
gastrointestinal tract [24, 73, 74], and likely their homol-
ogous roles in kidney.
Of special interest is the potent effect of ionic strength
to modulate the EC50 of the mammalian CaSR for extra-
cellular Ca2+ [75]. Reductions in ionic strength reduce the
Ca2+ EC50, while elevations in ionic strength increase the
EC50. Recent studies in marine teleosts (bony fish [76])
and elasmobranches (cartilaginous fish [4, 77, 78]) have
shown that the CaSR is expressed in tissues involved in
salt and water transport, or the regulation of these pro-
cesses. For example, the receptor is highly expressed in di-
verse nephron segments of these fish, including segments
that are homologous to the mammalian TAL [4, 76]. Since
seawater contains millimolar concentrations of Ca2+ and
Mg2+, fish might use the ionic strength effect on the re-
ceptor EC50 for Ca2+/Mg2+ to detect changes in ocean
salinity. Indeed, we have recently shown that the fish re-
ceptor is modulated by salinity (ionic strength), and that
fish use this mechanism to sense salinity (i.e., the CaSR
is the salinity thermostat for these marine species) [76].
Does this have relevance to the kidney? Ca2+ reabsorp-
tion through the paracellular pathway in the TAL is not
accompanied by water, and thus, the Ca2+ concentration
immediately adjacent to the basolateral surface would
rise appreciably. Such a rise in Ca2+ would activate the
basolateral CaSR, and immediately reduce NaCl and fur-
ther Ca2+ reabsorption (Fig. 4). The CaSR, however, has a
built-in mechanism to prevent this from happening. Since
NaCl reabsorption is functionally coupled to the paracel-
lular movement of divalent minerals, the ionic strength
near the basolateral membrane would also increase in
parallel with Ca2+. The increase in ionic strength would
reduce CaSR affinity for calcium, and prevent overacti-
vation of the receptor by the reabsorbed Ca2+. Thus, the
allosteric modification of the EC50 for Ca2+ by salinity
provides a “governor” that links the rates of NaCl and
Ca2+/Mg2+ reabsorptive engine.
Proof-of-concept—gain-of-function mutations in the
extracellular Ca2+-sensing receptor (CaSR) cause
Bartter syndrome type V
Bartter syndrome represents a group of autosomal-
recessive disorders unified by a common pathophysiol-
ogy of severe reductions in, or losses of, salt absorption by
the TAL [76, 79, 80]. Bartter individuals frequently also
have markedly elevated urinary calcium excretion, which
may lead to nephrocalcinosis. Mutations in five genes
(Fig. 2) that are expressed in the TAL cause Bartter syn-
drome, and the products of these genes either transport
salt (three genes; type I, Na-K-2Cl cotransporter gene,
SLC12A1; [81]; type II ROMK K+ channel gene, KCNJ1;
[82–85]; and type III, CLC-Kb Cl− channel gene Clcnk;
[86, 87]) or regulate salt transport (two genes; type IV,
BSND gene or barttin, a regulator of CLC-Ka/b chan-
nels [88]; and type V).
CONCLUSION
The effects of CaSR activation to inhibit salt
transporters in the TAL—what we have termed the
“furosemide-like” effect—suggest that a constitutively
overactive receptor could result in a Bartter phenotype.
Indeed, two recent studies have identified individuals
with gain-of-function mutations in the CaSR (autosomal-
dominant hypocalcemia) that result in the Bartter pheno-
type [89, 90]. These “experiments of nature” confirm the
“loop diuretic–like” effects of CaSR action on the human
TAL.
Reprint requests to Steven Hebert, Yale University School of Medicine,
Department of Physiology, 333 Cedar Street, SHM B147, P.O. Box
208026, SA115 New Haven, CT 06525–8026.
E-mail: steven.hebert@yale.edu
REFERENCES
1. BERNARD C: An Introduction To The Study Of Experimental
Medicine, Mineola, NY, Dover Publications, 1949
2. SMITH HW: From Fish to Philosopher, Boston, Little, Brown and
Company, 1953
3. BROWN EM, GAMBA G, RICCARDI D, et al: Cloning and characteriza-
tion of an extracellular Ca2+-sensing receptor from bovine parathy-
roid. Nature 366:575–580, 1993
4. GARRETT JE, CAPUANO IV, HAMMERLAND LG, et al: Molecular
cloning and functional expression of human parathyroid calcium
receptor cDNAs. J Biol Chem 270:12919–12925, 1995
5. RICCARDI D, PARK J, LEE WS, et al: Cloning and functional expres-
sion of a rat kidney extracellular calcium/polyvalent cation-sensing
receptor. Proc Natl Acad Sci U S A 92:131–135, 1995
6. RICCARDI D, LEE WS, LEE K, et al: Localization of the extracellular
Ca2+-sensing receptor and PTH/PTHrP receptor in rat kidney. Am
J Physiol 271:F951–F956, 1996
7. KIFOR O, DIAZ R, BUTTERS R, BROWN EM: The Ca2+-sensing re-
ceptor (CaR) activates phospholipases C, A2, and D in bovine
S-32 Hebert: Calcium and salinity sensing by the TAL
parathyroid and CaR-transfected, human embryonic kidney
(HEK293) cells. J Bone Miner Res 12:715–725, 1997
8. BRAUNER-OSBORNE H, JENSEN AA, SHEPPARD PO, et al: The agonist-
binding domain of the calcium-sensing receptor is located at the
amino-terminal domain. J Biol Chem 274:18382–18386, 1999
9. PETREL C, KESSLER A, DAUBAN P, et al: Positive and negative al-
losteric modulators of the Ca2+-sensing receptor interact within
overlapping but not identical binding sites in the transmembrane
domain. J Biol Chem 279:18990–18997, 2004
10. BAI M, TRIVEDI S, LANE CR, et al: Protein kinase C phosphorylation
of threonine at position 888 in Ca2+- sensing receptor (CaR) inhibits
coupling to Ca2+ store release. J Biol Chem 273:21267–21275, 1998
11. GAMA L, BREITWIESER GE: A carboxyl-terminal domain controls
the cooperativity for extracellular Ca2+ activation of the human
calcium sensing receptor. A study with receptor-green fluorescent
protein fusions. J Biol Chem 273:29712–29718, 1998
12. RAY K, FAN G-F, GOLDSMITH PK, SPIEGEL AM: The carboxyl termi-
nus of the human calcium receptor. Requirements for cell-surface
expression and signal transduction. J Biol Chem 272:31355–31361,
1997
13. BAI M, TRIVEDI S, BROWN EM: Dimerization of the extracellu-
lar calcium-sensing receptor (CaR) on the cell surface of CaR-
transfected HEK293 cells. J Biol Chem 273:23605–23610, 1998
14. BAI M, TRIVEDI S, KIFOR O, et al: Intermolecular interactions be-
tween dimeric calcium-sensing receptor monomers are important
for its normal function. Proc Natl Acad Sci USA 96:2834–2839, 1999
15. PACE AJ, GAMA L, BREITWIESER GE: Dimerization of the calcium-
sensing receptor occurs within the extracellular domain and is elim-
inated by Cys → Ser mutations at Cys101 and Cys236. J Biol Chem
274:11629–11634, 1999
16. WARD DT, BROWN EM, HARRIS HW: Disulfide bonds in the extra-
cellular calcium-polyvalent cation-sensing receptor correlate with
dimer formation and its response to divalent cations in vitro. J Biol
Chem 273:14476–14483, 1998
17. BROWN EM, POLLAK M, SEIDMAN CE, et al: Calcium-sensing cell-
surface receptors. New Engl J Med 333:234–240, 1995
18. BROWN EM, VASSILEV PM, HEBERT SC: Calcium ions as extracellular
messengers. Cell 83:679–682, 1995
19. BROWN EM, VASSILEV PM, QUINN S, HEBERT SC: G-protein-coupled,
extracellular Ca2+-sensing receptor: A versatile regulator of diverse
cellular functions. Vitam Horm 55:1–71, 1999
20. HEBERT SC: Extracellular calcium-sensing receptor: Implications
for calcium and magnesium handling in the kidney. Kidney Int
50:2129–2139, 1996
21. CHATTOPADHYAY N, CHENG I, ROGERS K, et al: Identification and
localization of extracellular Ca2+-sensing receptor in rat intestine.
Am J Physiol (Gastrointest Liver Physiol) 274:G122–G130, 1998
22. CHENG SX, AKUDA M, HALL AE, et al: Expression of calcium-sensing
receptor in rat colonic epithelium: Evidence for modulation of fluid
transport. Am J Physiol (Gastrointest Liver Physiol) 283:G240–
G250, 2002
23. HENTSCHEL H, NEARING J, HARRIS HW, et al: Localization of Mg2+-
sensing shark kidney calcium receptor SKCaR in kidney of dogfish,
Squalus acanthias. Am J Physiol Renal Physiol 285:F430–F439, 2003
24. HEBERT SC, CHENG SX, GEIBEL JP: Functions and roles of the ex-
tracellular Ca2+-sensing receptor in the gastrointestinal tract. Cell
Calcium 35:239–247, 2004
25. CHENG I, QURESHI I, CHATTOPADHYAY N, et al: Expression of an ex-
tracellular calcium-sensing receptor in rat stomach. Gastroenterol-
ogy 116:118–126, 1999
26. CHAKRABARTY S, RADJENDIRANE V, APPELMAN H, VARANI J: Extra-
cellular calcium and calcium sensing receptor function in human
colon carcinomas: Promotion of E-cadherin expression and sup-
pression of b-catenin/TCF activation. Cancer Res 63:67–71, 2003
27. BROWN EM, CHATTOPADHYAY N, VASSILEV PM, HEBERT SC: The
calcium-sensing receptor (CaR) permits Ca2+ to function as a versa-
tile extracellular first messenger. Recent Prog Horm Res 53:257–280,
1998
28. BROWN EM, HEBERT SC: Calcium-receptor-regulated parathyroid
and renal function. Bone 20:303–309, 1997
29. BROWN EM, POLLAK M, HEBERT SC: Cloning and characterization of
extracellular Ca2+-sensing receptors from parathyroid and kidney:
Molecular physiology and pathophysiology of Ca2+-sensing. The
Endocrinologist 4:419–426, 1994
30. BROWN EM, POLLAK M, RICCARDI D, HEBERT SC: Cloning and char-
acterization of an extracellular Ca2+-sensing receptor from parathy-
roid and kidney: New insights into the physiology and pathophysi-
ology of calcium metabolism. Nephrol Dial Transplant 9:1703–1706,
1994
31. HEBERT SC, BROWN EM: The extracellular calcium receptor. COCB
7:484–492, 1995
32. HEBERT SC, BROWN EM: The scent of an ion: Calcium-sensing and its
roles in health and disease. Curr Opin Nephrol Hypertens 5:45–53,
1996
33. HEBERT SC, BROWN EM, HARRIS HW, JR.: Role of Ca2+-sensing
receptors in divalent mineral ion homeostasis. J Exp Biol 200:295–
302, 1997
34. POLLAK MR, BROWN EM, CHOU Y-HW, et al: Mutations in the
Ca2+-sensing receptor gene cause familial hypocalciuric hypercal-
cemia and neonatal severe hyperparathyroidism. Cell 75:1297–1303,
1993
35. POLLAK MR, BROWN EM, ESTEP HL, et al: Autosomal dominant
hypocalcaemia caused by a Ca2+-sensing receptor gene mutation.
Nat Genet 8:303–307, 1994
36. HO C, CONNER DA, POLLAK MR, et al: A mouse model of human
familial hypocalciuric hypercalcemia and neonatal severe hyper-
parathyroidism. Nat Genet 11:389–394, 1995
37. BROWN EM: Kidney and bone: Physiological and pathophysiological
relationships, chap. 39, in Handbook of Physiology: Renal Physiol-
ogy, edited by Windhager EE, New York, Oxford University Press,
1992, pp 1841–1916
38. KUROKAWA K: The kidney and calcium homeostasis. Kidney Int
44:S97–S105, 1994
39. KUROKAWA K: Calcium-regulating hormones and the kidney. Kid-
ney Int 32:760–771, 1987
40. ATTIE MF, GILL JR, JR., STOCK JL, et al: Urinary calcium excre-
tion in familial hypocalciuric hypercalcemia. Persistence of relative
hypocalciuria after induction of hypoparathyroidism. J Clin Invest
72:667–676, 1983
41. TU Q, PI M, KARSENTY G, et al: Rescue of the skeletal phenotype in
CasR-deficient mice by transfer onto the Gcm2 null background. J
Clin Invest 111:1029–1037, 2003
42. VEZZOLI G, TANINI A, FERRUCCI L, et al: Influence of calcium-sensing
receptor gene on urinary calcium excretion in stone-forming pa-
tients. J Am Soc Nephrol 13:2517–2523, 2002
43. RICCARDI D, HALL AE, XU J, et al: Localization of the extracellular
Ca2+(polyvalent) cation-sensing receptor in kidney. Am J Physiol
(Renal Physiol) 274:F611–F622, 1998
44. DE ROUFFIGNAC C, QUAMME G: Renal magnesium handling and its
hormonal control. Physiol Rev 74:305–322, 1994
45. QUAMME GA, DIRKS JH: Intraluminal and contraluminal mag-
nesium on magnesium and calcium transfer in the rat nephron.
Am J Physiol (Renal Fluid Electrolyte Physiol) 238:F187–F198,
1980
46. FRIEDMAN PA: Codependence of renal calcium and sodium trans-
port. Annu Rev Physiol 60:179–197, 1998
47. MANDON B, SIGA E, ROINEL N, DE ROUFFIGNAC C: Ca2+, Mg2+ and
K+ transport in the cortical and medullary thick ascending limb of
the rat nephron: Influence of transepithelial voltage. Pflu¨gers Arch
424:558–560, 1993
48. DE ROUFFIGNAC C, DI STEFANO A, WITTNER M, et al: Consequences
of differential effects of ADH and other peptide hormones on thick
ascending limb of mammalian kidney. Am J Physiol (Regulatory
Integrative Comp Physiol) 260:R1023–R1035, 1991
49. DI STEFANO A, DE ROUFFIGNAC C, WITTNER M: Transepithelial Ca2+
and Mg2+ transport in the cortical thick ascending limb of Henle’s
loop of the mouse is a voltage-dependent process. Renal Physiol
Biochem 16:157–166, 1993
50. EL-HAJJ F, SEIFTER J, SCOTT J, BROWN EM: Calcium-regulated renal
calcium handling in healthy men: Relationship to sodium handling.
J Clin Endocrinol Metab 83:2366–2372, 1998
51. PATTARAGARN A, FOX J, ALON US: Effect of the calcimimetic NPS
R-467 on furosemide-induced nephrocalcinosis in the young rat.
Kidney Int 65:1684–1689, 2004
Hebert: Calcium and salinity sensing by the TAL S-33
52. JESUS FERREIRA MC, BAILLY C: Extracellular Ca2+ decreases chlo-
ride reabsorption in rat CTAL by inhibiting cAMP pathway. Am J
Physiol 275:F198–F203, 1998
53. WANG W-H, LU M, HEBERT SC: Phospholipase A2 is involved in
mediating the effect of Ca2+ on the apical K+ channels in rat TAL.
Am J Physiol (Renal Physiol) 273:F421–F429, 1997
54. DE ROUFFIGNAC C: Multihormonal regulation of nephron epithelia:
Achieved through combinational mode? Am J Physiol 269:R739–
R748, 1995
55. TAKAICHI K, KUROKAWA K: High Ca2+ inhibits peptide hormone-
dependent cAMP production specifically in thick ascending limbs
of Henle. Mineral Electrolyte Metab 12:342–346, 1986
56. TAKAICHI K, UCHIDA S, KUROKAWA K: High Ca2+ inhibits AVP-
dependent cAMP production in thick ascending limbs of Henle.
Am J Physiol (Renal Fluid Electrolyte Physiol) 250:F770–F776,
1986
57. JESUS FERREIRA MC, HELIES-TOUSSAINT C, IMBERT-TEBOUL M, et al:
Co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-
sensing receptor in the cortical thick ascending limb cell of the rat
kidney. Inhibition of hormone-dependent cAMP accumulation by
extracellular Ca2+. J Biol Chem 273:15192–15202, 1998
58. WANG W, LU M, BALAZY M, HEBERT SC: Phospholipase A2 is in-
volved in mediating the effect of extracellular Ca2+ on apical K+
channels in rat TAL. Am J Physiol 273:F421–F429, 1997
59. ESCALANTE B, ERLIJ D, FALCK JR, MCGIFF JC: Effect of cytochrome
P450 arachidonate metabolites on ion transport in rabbit kidney
loop of Henle. Science 251:799–802, 1991
60. ESCALANTE B, ERLIJ D, FALCK JR, MCGIFF JC: Ion transport inhi-
bition in the medullary thick ascending limb of Henle’s loop by
cytochrome P450-arachidonic acid metabolites. Adv Prostaglandin
Thromboxane Leukot Res 21:209–212, 1991
61. ZOU AP, DRUMMOND HA, ROMAN RJ: Role of 20–HETE in elevating
loop chloride reabsorption in Dahl SS/Jr rats. Hypertension 27:631–
635, 1996
62. AMLAL H, LEGOFF C, VERNIMMEN C, et al: Na+-K+(NH4+)-2Cl−
cotransport in medullary thick ascending limb: Control by PKA,
PKC, and 20–HETE. Am J Physiol (Cell Physiol) 271:C455–C463,
1997
63. HEBERT SC, ANDREOLI TE: Control of NaCl transport in the thick
ascending limb. Am J Physiol (Renal Fluid Electrolyte Physiol)
246:F745–F756, 1984
64. WANG WH, LU M, HEBERT SC: Cytochrome P-450 metabolites me-
diate extracellular Ca2+-induced inhibition of apical K+ channels
in the TAL. Am J Physiol 271:C103–C111, 1996
65. GOOD DW, GEORGE T, WANG DH: Angiotensin II inhibits HCO3−
absorption via a cytochrome P-450-dependent pathway in MTAL.
Am J Physiol 276:F726–F736, 1999
66. LU M, ZHU Y, BALAZY M, et al: Effect of angiotensin II on the
apical K+ channel in the thick ascending limb of the rat kidney. J
Gen Physiol 108:537–547, 1996
67. GRIDER JS, FALCONE JC, KILPATRICK EL, et al: P450 arachido-
nate metabolites mediate bradykinin-dependent inhibition of NaCl
transport in the rat thick ascending limb. Can J Physiol Pharmacol
75:91–96, 1997
68. FIRSOV D, AARAB L, MANDON B, et al: Arachidonic acid inhibits
hormone-stimulated cAMP accumulation in the medullary thick as-
cending limb of the rat kidney by a mechanism sensitive to pertussis
toxin. Pflu¨gers Arch 429:636–646, 1995
69. FERRERI NR, MCGIFF JC, VIO CP, CARROLL MA: TNFa regulates
renal COX-2 in the rat thick ascending limb (TAL). Thromb Res
110:277–280, 2003
70. WANG D, AN SJ, WANG WH, et al: CaR-mediated COX-2 expres-
sion in primary cultured mTAL cells. Am J Physiol Renal Physiol
281:F658–F664, 2001
71. WANG D, PEDRAZA PL, ABDULLAH HI, et al: Calcium-sensing
receptor-mediated TNF production in medullary thick ascending
limb cells. Am J Physiol Renal Physiol 283:F963–F970, 2002
72. CULPEPPER RM, ANDREOLI TE: PGE2, forskolin, and cholera toxin
interactions modulating NaCl transport in mouse mTALH. Am J
Physiol (Renal Fluid Electrolyte Physiol) 247–16:F784–F792, 1984
73. CHENG SX, GEIBEL JP, HEBERT SC: Extracellular polyamines regu-
late fluid secretion in rat colonic crypts via the extracellular calcium-
sensing receptor. Gastroenterology 126:148–158, 2004
74. CONIGRAVE AD, FRANKS AH, BROWN EM, QUINN SJ: L-amino acid
sensing by the calcium-sensing receptor: A general mechanism for
coupling protein and calcium metabolism? Eur J Clin Nutr 56:1072–
1080, 2002
75. QUINN SJ, KIFOR O, TRIVEDI S, et al: Sodium and ionic strength
sensing by the calcium receptor. J Biol Chem 273:19579–19586, 1998
76. NEARING J, BETKA M, QUINN S, et al: Polyvalent cation receptor
proteins (CaRs) are salinity sensors in fish. Proc Natl Acad Sci USA
99:9231–9236, 2002
77. FELLNER SK, PARKER L: A Ca2+-sensing receptor modulates shark
rectal gland function. J Exp Biol 205:1889–1897, 2002
78. FELLNER SK, PARKER L: Ionic strength and the polyvalent cation
receptor of shark rectal gland and artery. J Exp Zoolog Part A
Comp Exp Biol 301:235–239, 2004
79. BETTINELLI A, CIARMATORI S, CESAREO L, et al: Phenotypic variabil-
ity in Bartter syndrome type I. Pediatr Nephrol 14:940–945, 2000
80. HEBERT SC: Bartter syndrome. Curr Opin Nephrol Hypertens
12:527–532, 2003
81. SIMON DB, LIFTON RP: Mutations in Na(K)Cl transporters in Gitel-
man’s and Bartter’s syndromes. Curr Opin Cell Biol 10:450–454,
1998
82. JECK N, DERST C, WISCHMEYER E, et al: Functional heterogeneity
of ROMK mutations linked to hyperprostaglandin E syndrome.
Kidney Int 59:1803–1811, 2001
83. KAROLYIL L, KONRAD M, KOCKERLING A, et al: Mutations in the gene
encoding the inwardly-rectifying renal potassium channel, ROMK,
cause the antenatal variant of Bartter syndrome: Evidence for ge-
netic heterogeneity. Hum Molec Genet 6:17–26, 1997
84. SIMON DB, KARET FE, RODRIGUEZ-SORIANO J, et al: Genetic het-
erogeneity of Bartter’s syndrome revealed by mutations in the K+
channel, ROMK. Nat Genet 14:152–156, 1996
85. STARREMANS PG, VAN DER KEMP AW, KNOERS NV, et al: Functional
implications of mutations in the human renal outer medullary potas-
sium channel (ROMK2) identified in Bartter syndrome. Pflugers
Arch 443:466–472, 2002
86. KONRAD M, VOLLMER M, LEMMINK HH, et al: Mutations in the chlo-
ride channel gene CLCNKB as a cause of classic Bartter syndrome.
J Am Soc Nephrol 11:1449–1459, 2000
87. SIMON DB, BINDRA RS, MANSFIELD TA, et al: Mutations in the chlo-
ride channel gene, CLCNKB, cause Bartter’s syndrome type III.
Nat Genet 17:171–178, 1997
88. BIRKENHAGER R, OTTO E, SCHURMANN MJ, et al: Mutation of BSND
causes Bartter syndrome with sensorineural deafness and kidney
failure. Nat Genet 29:310–314, 2001
89. VARGAS-POUSSOU R, HUANG C, HULIN P, et al: Functional character-
ization of a calcium-sensing receptor mutation in severe autosomal
dominant hypocalcemia with a Bartter-like syndrome. J Am Soc
Nephrol 13:2259–2266, 2002
90. WATANABE S, FUKUMOTO S, CHANG H, et al: Association between
activating mutations of calcium-sensing receptor and Bartter’s syn-
drome. Lancet 360:692–694, 2002
